Published review outlines the multi-target formulation and nano-delivery mechanism; a 500-patient randomized controlled trial is underway to evaluate clinical outcomes
A peer-reviewed paper published in the International Journal of Scientific Research (Vol. 15, Issue 7, July 2026; DOI: 10.36106/ijsr) outlines the scientific rationale behind Q-NiFlex™, a multi-component nutraceutical for joint health, and its proprietary Phytosome Quantum Nano Sphere (PQNS™) delivery technology.
The paper, authored by Dr. Pallavi Singh (BDS, MDS, Government Hospital, Indore, M.P.) and Dr. Raj Bhan Singh (MD Anesthesiology, Assistant Professor, ESIC Medical College & Hospital, Indore, M.P.), reviews how PQNS™ combines phytosome complexation with nano-sized vesicular delivery — an approach intended to improve the stability, gastrointestinal protection, and systemic bioavailability of phytoconstituents that are otherwise poorly absorbed, such as curcumin and other botanical extracts.
Q-NiFlex™ combines glucosamine sulphate, chondroitin sulphate, hyaluronic acid, Boswellia serrata, Curcuma longa, Cissus quadrangularis, and a range of complementary botanicals, amino acids, vitamins, and minerals in a once-daily tablet, formulated to address five functional domains relevant to osteoarthritis: structural cartilage support, inflammation modulation, oxidative stress reduction, connective tissue regeneration, and delivery optimization.
“Osteoarthritis is a multifactorial condition, and single-ingredient supplements have struggled to address that complexity,” the authors note in the paper. “Q-NiFlex™ was developed on a multi-target philosophy, and PQNS™ is the delivery system intended to make that formulation more bioavailable.”
Clinical study underway
The paper is explicit that mechanistic rationale is not the same as clinical proof. A prospective, randomized, placebo-controlled study is currently underway to evaluate the efficacy and safety of Q-NiFlex™ in approximately 500 osteoarthritis patients, with a 12-week treatment period and follow-up to 16 weeks. Primary endpoints include change in WOMAC score from baseline; secondary endpoints include VAS pain scores, physician global assessment, and safety labs.
“Independent, peer-reviewed clinical trial results will be essential to validate the proposed advantages of PQNS™ technology,” the authors write. No efficacy claims are made pending that trial’s results.
About the PQNS™ platform
PQNS™ is a phytosome- and nano-vesicular delivery platform developed by Integria Care, designed to improve the absorption and stability of poorly bioavailable actives.
